HERSTAL, Belgium, Sept. 17, 2013 /CNW/ - EUROHEADPAIN is a major research project on Migraines and is financed by the European Union. Working alongside the eleven academic research centers, from ten different countries, is just one company: CEFALY Technology (STX-Med).
Migraine affects 15% of the population of Europe and is ranked among the 12 most debilitating disorders according to WHO. Current medical treatments are only moderately effective and are often not well tolerated. In addition, some of these patients are experiencing a shift towards chronic migraine (headaches for 15 days or more per month). One of the factors behind this shift towards chronic migraines is the overuse of migraine medications.
The research project, which will last for 3 years, will start in February 2014 and focus on several different aspects. One chapter will be dedicated to evaluating the effectiveness and analysis of the modes of action of neuromodulation, which is the use of micro-pulses and/or very weak electrical currents to act on certain parts of the nervous system to prevent and/or treat chronic migraines.
CEFALY-Technology (STX-Med) will design and develop the new neuromodulation techniques that will be tested in a university setting as part of the EUROHEADPAIN research project.
CEFALY Technology (STX-Med) is a recently created Belgian (Liège) SME specializing in electronics for medical applications. The company has developed a unique external cranial stimulation technology for several applications in the field of neurology, and in particular for treating migraines and headaches.
SOURCE: CEFALY Technology (STX-Med)
For further information: